AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine…
AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential…
Read More...
Read More...